Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Case Report

Volume 12, Number 2, April 2023, pages 100-104


Acute Promyelocytic Leukemia Treatment Masking Hepatic Tuberculosis: A Management Dilemma

Figures

Figure 1.
Figure 1. Peripheral blood smear demonstrating Auer rod within a promyelocyte.
Figure 2.
Figure 2. (a) H&E of liver biopsy specimen demonstrating necrotizing granulomas (red arrows). (b) Liver biopsy demonstrating two acid bacilli (white arrows).

Table

Table 1. Laboratory Values
 
DaySignificant eventSGOT (14 - 33 IU/L)ALT (10 - 42 IU/L)TB (0.2 - 1.0 mg/dL)Alkaline phosphatase (40 - 129 IU/L)
ATO: arsenic trioxide; ATRA: all-trans retinoic acid; SGOT: serum glutamic-oxaloacetic transaminase; TB: total bilirubin.
133261.591
2ATRA started22221.278
3Idarubicin started22201.275
440211.383
9661021.9112
10ATO started61891.2121
1170911.3122
251461362.8254
261721463.6259
27Chemotherapy held1921673.8261
302322313.4380
333645424.4408
34ATRA + 50% ATO dose restarted3205744.9382
361985104.6355
38Hepatic TB diagnosed; chemotherapy held1494436.7445
39TB treatment started1534035.0414
432445214.1487
44ATRA resumed1795014.4497
472444963.1414
49ATO restarted at 50% dose1634132.5334
511253372.9312
56831642.4405
76ATO resumed at 100%58572.3441
15631620.881